Market Place
Sourcing Support
Data Compilation #PharmaFlow
Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments
This year has seen pivotal advancements in medical innovation. The US Food and Drug Administration (
DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions
Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutica
US, Europe turn to advanced manufacturing, stockpiling to strengthen drug supply chains
Over the last few decades, the United States and Europe have saved trillions of dollars by importing
2024 US Elections: Harris, Trump differ on abortion rights, ACA, public health spends; agree on need to cut drug prices
The US is in the
midst of yet another, or perhaps the most, polarizing Presidential election.
The
BMS, Bayer, Takeda, Pfizer downsize to combat cost pressures, meet restructuring plans
Over
the last two years, there has been a significant surge in layoffs by
pharmaceutical and biote
Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination
The pharmaceutical industry has long recognized the critical role
excipients or inactive ingredient
US drug shortages hit record high in Q1 2024, impacts cancer, ADHD drugs; Lilly, Novo ramp up production
Drug shortages are threatening healthcare systems the world over.
Be it the US, Canada, Europe or A
Novartis, GSK, Sanofi, BMS shell out over US$ 10 bn in dealmaking, as mid-size deals take centerstage in 2024
The world of pharmaceuticals and biotechnology continued to evolve
this year with strategic allianc
CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities
During the first half (H1) of 2024, the global contract development and manufacturing organization (
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
FDA approves record eight biosimilars in H1 2024; okays first interchangeable biosimilars for Eylea
Biologics, or complex drugs that are derived from living organisms, have revolutionized treatment of
Big Pharma bets big on AI’s US$ 148 bn potential to revolutionize healthcare industry
Artificial intelligence (AI) is changing the world and bringing
efficiencies across all industries.
DMF submissions from China jump 42% as India continues to top list in Q1 2024
Generic drugs play a crucial role in providing access to life-saving drugs at affordable prices. To
Top Pharma Companies & Drugs in 2023: Merck’s Keytruda emerges as top-selling drug; Novo, Lilly sales skyrocket
The pharma industry clearly recalibrated itself in 2023, turning its focus away from Covid and onto
FDA approves four oligonucleotide therapies in 2023; Novartis, GSK, Novo bet big
In the intricate world of molecular biology, oligonucleotides stand out as versatile, powerful molec
FDA steps in to address challenges faced by cell and gene therapies
The year 2023 was a rather
tough one for cell and gene therapy (CGT) companies. There was news abou
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
Pfizer’s buyout of Seagen, drugmakers suing US govt, obesity drugs make it to top 10 Phispers of 2023
Every week,
PharmaCompass compiles important developments in the world of pharmaceuticals
and brin
Job cuts double in 2023; Pfizer, BMS, Novartis, Biogen downsize to cut costs
The year 2023 has
seen considerable job cuts by biopharmaceutical companies. While layoffs have
be
Drug shortages persist in US, Europe; Astra’s RSV therapy faces overwhelming demand
Both the US and Europe have been grappling with acute drug shortages since the start of the pandemic
India continues to top FDA-registered generics facilities, sets up 20 new units for FY24
Every year, the
US Food and Drug Administration (FDA) publishes the user fee amounts it will
colle
CDMO Activity Tracker: Novo taps Patheon to augment Wegovy supply; Wuxi sets up standalone vaccine plant
The third quarter (Q3) of 2023 was marked by deals and capacity expansions in the contract developme
Excipient Market Overview: Biologics spur growth in lipid-based agents; Asahi Kasei opens new plant
This week, PharmaCompass analyzes the market for excipients, or inactive ingredients used in pharmac
M&A deals surge in H1 2023, as Pfizer, Merck, Sanofi, Lilly announce buyouts
After a year when dealmaking faced several challenges, such as high interest rates and inflation and
FDA reports 62.5% growth in new drug approvals in H1 2023; Health Canada sees drop
After a year when
drug approvals by the US Food and Drug Administration
(FDA) slipped to the lowes
FDA’s June 2023 list of off-patent, off-exclusivity drugs sees steep rise in new drug applications
This week, PharmaCompass brings you the key highlights of the US Food and Drug Administration’
DMF submissions touch five-year high in H1 2023; China springs back with 46.5% rise in filings
With the pandemic
clearly behind us, generic active pharmaceutical ingredient (API) manufacturers
